Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Anti-EGFR (Panitumumab), humanized antibody
Human Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| E |
|---|---|
| Primary Accession | AAI18666 |
| Reactivity | Human |
| Host | Human |
| Clonality | Monoclonal |
| Isotype | Human IgG1 |
| Application & Usage | Neutralization : 1-20 µg/ml; ELISA: 1 µg/ml |
|---|---|
| Alias Symbol | EGFR |
| Other Names | Vectibix |
| Appearance | Colourless liquid |
| Formulation | 100 ug (2mg/ml) of antibody in Phosphate buffered saline, pH 7.4. |
| Reconstitution & Storage | -20 °C |
| Background Descriptions | |
| Precautions | Anti-EGFR (Panitumumab), humanized antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Panitumumab is the human monoclonal antibody against epidermal growth factor receptor (EGFR). The EGFR is a member of a subfamily of type I receptor tyrosine kinases, including EGFR (HERl, c-ErbB-l), HER2/neu, HER3, and HER4. EGFR is a transmembrane glycoprotein that is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle. Overexpression of EGFR is also detected in many human cancers, including those of the colon and rectum. Panitumumab binds specifically and selectively to the EGFR, preventing binding of activating ligands, such as the EGF and transforming growth factor-α. This binding results in blockade of the essential downstream signaling pathways that are known to govern apoptosis, proliferation and differentiation of both normal and neoplastic cell types in a wide array of tissues.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
